Literature DB >> 31126001

The risk of recurrent stroke at 24 months in patients with symptomatic carotid near-occlusion: results from CAOS, a multicentre registry study.

A García-Pastor1, A Gil-Núñez1, J M Ramírez-Moreno2, N González-Nafría3, J Tejada3, F Moniche4, J C Portilla-Cuenca5, P Martínez-Sánchez6, B Fuentes6, M Á Gamero-García7, M Alonso de Leciñana8, J Masjuán8, D Cánovas-Verge9, Y Aladro10, V Parkhutik11, A Lago-Martín11, A M de Arce-Borda12, M Usero-Ruíz13, R Delgado-Mederos14, A Pampliega15, Á Ximenez-Carrillo16, M Bártulos-Iglesias17, E Castro-Reyes1.   

Abstract

BACKGROUND AND
PURPOSE: The risk of recurrent stroke amongst patients with symptomatic carotid near-occlusion (SCNO) has not been clearly established, and its management remains controversial. The aim was to define the 24-month risk of recurrent stroke and to analyse the effect of the different treatment modalities (medical treatment and revascularization) in a population of patients with SCNO.
METHODS: A multicentre, nationwide, prospective study from January 2010 to May 2016 was performed. Patients with angiography-confirmed SCNO were included. The primary end-point was ipsilateral ischaemic stroke including periprocedural events within 24 months following the presenting event. Revascularization results and periprocedural complications, ipsilateral transient ischaemic attack, disabling or fatal stroke, and mortality were also noted.
RESULTS: The study population comprised 141 patients from 17 Spanish centres. Seventy patients (49.6%) were treated by revascularization (carotid stenting in 47, endarterectomy in 23). Complete revascularization was achieved in 58 patients (83%). Periprocedural stroke or death occurred in 5.7%. The 24-month cumulative incidence of the primary end-point was 11.1% (95% confidence interval 5.8-16.4; n = 15), 12% in the medical treatment group and 10.2% in the revascularization group, log-rank P = 0.817. The cumulative rates of ipsilateral ischaemic stroke or transient ischaemic attack, disabling or fatal stroke, and mortality, were 17%, 4.5% and 7.5%, respectively.
CONCLUSIONS: The rate of ipsilateral ischaemic stroke in patients with SCNO seems to be lower than the known rate associated with severe carotid stenosis without near-occlusion. The potential benefit of revascularization in the prevention of stroke in patients with SCNO may be influenced by the effectiveness and safety of the procedure. © European Academy of Neurology 2019.

Entities:  

Keywords:  carotid near-occlusion; carotid stenosis; recurrence; revascularization; risk; stroke

Year:  2019        PMID: 31126001     DOI: 10.1111/ene.14006

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  2 in total

1.  Comment on the article "Symptomatic carotid near-occlusion causes a high risk of recurrent ipsilateral ischemic stroke" by Gu et al.

Authors:  Andrés García-Pastor; Antonio Gil-Núñez; José María Ramírez-Moreno; Noelia González-Nafría; Javier Tejada; Francisco Moniche; Juan Carlos Portilla-Cuenca; Patricia Martínez-Sánchez; Blanca Fuentes; Miguel Ángel Gamero-García; María Alonso de Leciñana; David Cánovas-Verge; Yolanda Aladro; Aida Lago-Martín; Ana María de Arce-Borda; María Usero-Ruíz; Juan F Arenillas; Raquel Delgado-Mederos; Ana Pampliega; Álvaro Ximenez-Carrillo; Mónica Bártulos-Iglesias; Enrique Castro-Reyes
Journal:  J Neurol       Date:  2019-12-14       Impact factor: 4.849

2.  Endarterectomy, Stenting, or Medical Treatment for Symptomatic Carotid Near-Occlusion: Results from CAOS, a Multicenter Registry Study.

Authors:  A Garcia-Pastor; A Gil-Núñez; J M Ramirez-Moreno; N González-Nafría; J Tejada; F Moniche; J C Portilla-Cuenca; P Martínez-Sánchez; B Fuentes; M A Gamero-García; M A de Leciñana; J Masjuan; D C Verge; Y Aladro; V Parkhutik; A Lago; A M de Arce-Borda; M Usero-Ruiz; R Delgado-Mederos; A Pampliega; Á Ximenez-Carrillo; M Bártulos-Iglesias; E Castro-Reyes
Journal:  AJNR Am J Neuroradiol       Date:  2022-08-18       Impact factor: 4.966

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.